Compare Brown-Forman Corporation Class B (BF.B) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Brown-Forman Corporation Class B vs Summit Therapeutics Inc — how do they compare? Brown-Forman Corporation Class B trades at $27.96, while Summit Therapeutics Inc trades at $15.22 (market cap $12.06B). The key difference: Brown-Forman Corporation Class B is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| BF.B | SMMT | |
|---|---|---|
Sector | Consumer Staples | Health |
52-Week High | $31.26 | $26.98 |
52-Week Low | $22.80 | $12.55 |
Market Cap | — | $12.06B |
Enterprise Value | — | $11.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Brown-Forman Class B (BF.B) trades at $28.03, down 0.57% on the day. The stock shows a bullish technical trend with moving averages supporting upside, while oscillators are neutral. Recent earnings have beaten expectations in three of the last four quarters, with Q2 2024 EPS of $0.48 exceeding the $0.46 estimate. Analyst sentiment is mixed, with a 25% buy rating amid divided coverage.
The outlook is cautiously optimistic given earnings momentum, but risks include competitive pressures and market volatility. Investment appeal hinges on sustained profit growth, though the lack of clear valuation metrics and mixed analyst views suggest a balanced risk-reward profile for investors.
Summit Therapeutics (SMMT) trades at $15.42, up 3.7% with a bullish technical signal. The company shows negative profitability with ROE at -192.5% and net loss of $1.08B for 2025, but maintains positive analyst sentiment with 14 buy ratings and a $27.90 consensus price target. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials.
The investment case hinges on ivonescimab's regulatory approval potential, offering significant upside if successful. However, substantial risks include ongoing losses, cash burn requiring financing, and regulatory uncertainty. Current technical strength suggests momentum, but fundamental challenges require careful risk assessment for speculative biotech investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Brown-Forman Corporation Class B
Brown-Forman is the largest U.S.-domiciled producer of distilled spirits. The firm reports only a single operating segment, and whiskey represents its primary business driver, generating roughly three-quarters of sales, undergirded by the Jack Daniel's brand as well as bourbons such as Woodford Reserve and Old Forrester. Notable nonwhiskey offerings include tequilas such as el Jimador and Herradura. The firm operates globally, with products sold in more than 170 countries, and adapts its route-to-consumer model depending on regulation as well as the prevailing competitive dynamics in a given market. For example, it sells through distributors in the U.S. but operates its own logistics apparatus in many other countries. The company remains under the control of the Brown family.
Read more on BF.B →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
